These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 18433113)

  • 1. Discovery of potent, orally bioavailable, selective 5-HT1A/B/D receptor antagonists.
    Ward SE; Eddershaw PJ; Scott CM; Gordon LJ; Lovell PJ; Moore SH; Smith PW; Starr KR; Thewlis KM; Watson JM
    J Med Chem; 2008 May; 51(10):2887-90. PubMed ID: 18433113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3-(Piperazinylpropyl)indoles: selective, orally bioavailable h5-HT1D receptor agonists as potential antimigraine agents.
    Chambers MS; Street LJ; Goodacre S; Hobbs SC; Hunt P; Jelley RA; Matassa VG; Reeve AJ; Sternfeld F; Beer MS; Stanton JA; Rathbone D; Watt AP; MacLeod AM
    J Med Chem; 1999 Feb; 42(4):691-705. PubMed ID: 10052976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and SAR of highly potent dual 5-HT1A and 5-HT1B antagonists as potential antidepressant drugs.
    Kling A; Lange UE; Mack H; Bakker MH; Drescher KU; Hornberger W; Hutchins CW; Möller A; Müller R; Schmidt M; Unger L; Wicke K; Schellhaas K; Steiner G
    Bioorg Med Chem Lett; 2005 Dec; 15(24):5567-73. PubMed ID: 16219465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 8-Piperazinyl-2,3-dihydropyrrolo[3,2-g]isoquinolines: potent, selective, orally bioavailable 5-HT1 receptor ligands.
    Heightman TD; Gaster LM; Pardoe SL; Pilleux JP; Hadley MS; Middlemiss DN; Price GW; Roberts C; Scott CM; Watson JM; Gordon LJ; Holland VA; Powles J; Riley GJ; Stean TO; Trail BK; Upton N; Austin NE; Ayrton AD; Coleman T; Cutler L
    Bioorg Med Chem Lett; 2005 Oct; 15(19):4370-4. PubMed ID: 16039851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The synthesis and biological evaluation of quinolyl-piperazinyl piperidines as potent serotonin 5-HT1A antagonists.
    Childers WE; Havran LM; Asselin M; Bicksler JJ; Chong DC; Grosu GT; Shen Z; Abou-Gharbia MA; Bach AC; Harrison BL; Kagan N; Kleintop T; Magolda R; Marathias V; Robichaud AJ; Sabb AL; Zhang MY; Andree TH; Aschmies SH; Beyer C; Comery TA; Day M; Grauer SM; Hughes ZA; Rosenzweig-Lipson S; Platt B; Pulicicchio C; Smith DE; Sukoff-Rizzo SJ; Sullivan KM; Adedoyin A; Huselton C; Hirst WD
    J Med Chem; 2010 May; 53(10):4066-84. PubMed ID: 20443629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 1,3-Dioxolane-based ligands as rigid analogues of naftopidil: structure-affinity/activity relationships at alpha1 and 5-HT1A receptors.
    Sorbi C; Franchini S; Tait A; Prandi A; Gallesi R; Angeli P; Marucci G; Pirona L; Poggesi E; Brasili L
    ChemMedChem; 2009 Mar; 4(3):393-9. PubMed ID: 19152363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a potent and selective 5-HT1B receptor antagonist.
    Wyman PA; Marshall HR; Flynn ST; King RJ; Thompson M; Smith PW; Hadley MS; Price GW; Scott CM; Dawson LA
    Bioorg Med Chem Lett; 2005 Nov; 15(21):4708-12. PubMed ID: 16153839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-[omega-[4-(2-methoxyphenyl)-1-piperazinyl]alkyl]-2-quinolinamines as high-affinity fluorescent 5-HT1A receptor ligands.
    Lacivita E; Leopoldo M
    J Med Chem; 2008 Mar; 51(5):1492-5. PubMed ID: 18269229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and in-vitro pharmacological evaluation of new 5-HT1A receptor ligands containing a benzotriazinone nucleus.
    Fiorino F; Severino B; De Angelis F; Perissutti E; Frecentese F; Massarelli P; Bruni G; Collavoli E; Santagada V; Caliendo G
    Arch Pharm (Weinheim); 2008 Jan; 341(1):20-7. PubMed ID: 18072244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Further studies on the interaction of the 5-hydroxytryptamine3 (5-HT3) receptor with arylpiperazine ligands. development of a new 5-HT3 receptor ligand showing potent acetylcholinesterase inhibitory properties.
    Cappelli A; Gallelli A; Manini M; Anzini M; Mennuni L; Makovec F; Menziani MC; Alcaro S; Ortuso F; Vomero S
    J Med Chem; 2005 May; 48(10):3564-75. PubMed ID: 15887964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of the first potent, selective 5-hydroxytryptamine1D receptor antagonist.
    Ward SE; Harrington FP; Gordon LJ; Hopley SC; Scott CM; Watson JM
    J Med Chem; 2005 May; 48(10):3478-80. PubMed ID: 15887956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo/ex vivo and behavioural study on central effects of 5-HT1B/1D and 5-HT1A antagonists in guinea pigs.
    Rex A; Voigt JP; Wicke KM; Fink H
    Pharmacol Biochem Behav; 2008 Jan; 88(3):196-204. PubMed ID: 17888505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological evaluation of benzodioxanylpiperazine derivatives as potent serotonin 5-HT(1A) antagonists: the discovery of Lecozotan.
    Childers WE; Abou-Gharbia MA; Kelly MG; Andree TH; Harrison BL; Ho DM; Hornby G; Huryn DM; Potestio L; Rosenzweig-Lipson SJ; Schmid J; Smith DL; Sukoff SJ; Zhang G; Schechter LE
    J Med Chem; 2005 May; 48(10):3467-70. PubMed ID: 15887953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies on a series of potent, orally bioavailable, 5-HT(1) receptor ligands--part II.
    Ward SE; Eddershaw P; Flynn ST; Gordon L; Lovell PJ; Moore SH; Scott CM; Smith PW; Thewlis KM; Wyman PA
    Bioorg Med Chem Lett; 2009 Jan; 19(2):428-32. PubMed ID: 19071020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis of potent and selective serotonin 5-HT1B receptor ligands.
    Huang Y; Bae SA; Roth BL; Laruelle M
    Bioorg Med Chem Lett; 2005 Nov; 15(21):4786-9. PubMed ID: 16143528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlating efficacy in rodent cognition models with in vivo 5-hydroxytryptamine1a receptor occupancy by a novel antagonist, (R)-N-(2-methyl-(4-indolyl-1-piperazinyl)ethyl)-N-(2-pyridinyl)-cyclohexane carboxamide (WAY-101405).
    Hirst WD; Andree TH; Aschmies S; Childers WE; Comery TA; Dawson LA; Day M; Feingold IB; Grauer SM; Harrison BL; Hughes ZA; Kao J; Kelly MG; van der Lee H; Rosenzweig-Lipson S; Saab AL; Smith DL; Sullivan K; Rizzo SJ; Tio C; Zhang MY; Schechter LE
    J Pharmacol Exp Ther; 2008 Apr; 325(1):134-45. PubMed ID: 18182558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [N-methyl-3H3]AZ10419369 binding to the 5-HT1B receptor: in vitro characterization and in vivo receptor occupancy.
    Maier DL; Sobotka-Briner C; Ding M; Powell ME; Jiang Q; Hill G; Heys JR; Elmore CS; Pierson ME; Mrzljak L
    J Pharmacol Exp Ther; 2009 Jul; 330(1):342-51. PubMed ID: 19401496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, in vitro and in vivo 5-HT1A/5-HT2A serotonin receptor activity of new hybrid 1,2,3,4-tetrahydro-gamma-carbolines with 1-(2-methoxyphenyl)piperazine moiety.
    Boksa J; Charakchieva-Minol S; Duszyńska B; Bugno R; Kłodzińska A; Tatarczyńska E; Chojnacka-Wójcik E; Bojarski AJ
    Pol J Pharmacol; 2003; 55(6):1013-9. PubMed ID: 14730096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-activity relationship studies of CNS agents, Part 20: 9-(omega-[1-(m-chlorophenyl)-4-piperazinyl]alkyl]-1,2,3,4-tetra-hydro- beta-carbolines: new 5-HT1A and 5-HT2A receptor ligands.
    Boksa J; Duszynńska B; Mokrosz JL
    Pharmazie; 1995 Mar; 50(3):220-1. PubMed ID: 7732057
    [No Abstract]   [Full Text] [Related]  

  • 20. QSAR study on dual 5-HT1A and 5-HT1B antagonists: an insight into the structural requirement for antidepressant activity.
    Dessalew N
    Arch Pharm (Weinheim); 2008 May; 341(5):314-22. PubMed ID: 18389517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.